Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Tenaya Therapeutics (NASDAQ: TNYA) announced it will present initial data from Cohort 1 of the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on December 17, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA) announced it will present initial data from Cohort 1 of the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on December 17, 2024. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. The presentation will be accessible through the company's website, with a replay available afterward in the Investor Relations section.
Details
News Market Reaction – TNYA
The recorded move for TNYA in the trading session of this news was -51.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17.
Conference Call and Webcast
Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here. The live webcast will be available under the "Events” section of the Investor Relations page of the Tenaya website at investors.tenayatherapeutics.com.
An archived replay of the webcast will be available on Tenaya’s website.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.